Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection

CompletedOBSERVATIONAL
Enrollment

693

Participants

Timeline

Start Date

April 21, 2020

Primary Completion Date

April 19, 2022

Study Completion Date

April 19, 2022

Conditions
COVID-19
Interventions
DIAGNOSTIC_TEST

Outpatient MRI

"Participation in the study includes up to 3 visits to a partnering imaging facility - this will include measurement of height and weight (to calculate BMI), blood pressure measurement, 3 sets of blood tests, 3 Questionnaires and 3 MRI tests.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications."

Trial Locations (2)

W1B 1PT

Mayo Clinic Healthcare, London

OX4 2LL

Gemini, Oxford

All Listed Sponsors
lead

Perspectum

INDUSTRY

NCT04369807 - Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection | Biotech Hunter | Biotech Hunter